查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2095045

口腔黏膜給藥系統市場－2026-2032年全球市場預測

Buccal Drug Delivery Systems Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，口腔黏膜給藥系統市場將成長至 64.2 億美元，複合年成長率為 6.74%。

主要市場統計數據
基準年 2025 40.6億美元
預計年份：2026年 43.3億美元
預測年份 2032 64.2億美元
複合年成長率 (%) 6.74%

口腔粘膜藥物遞送系統執行摘要

隨著醫療保健專業人員、藥物研發人員和保險公司尋求能夠提高患者依從性、避免首過代謝並實現透過口腔黏膜快速、可控地全身吸收的劑型，口腔給藥系統的戰略重要性日益凸顯。這些系統包括口腔膜、片劑、貼片、噴霧劑、凝膠和黏膜黏附製劑，旨在與口腔黏膜保持足夠時間的接觸，從而有效釋放活性成分。在吞嚥困難、擔心胃腸道分解、需要無針給藥或需要快速起效的治療中，這些系統的臨床價值尤其顯著。

口腔黏膜給藥領域的變革性變化

隨著藥物科學的研究方向從改進傳統口服劑型轉向針對特定用途設計的黏膜滲透平台，口腔黏膜給藥領域正經歷變革。其中一個主要轉變是黏膜附著性聚合物的廣泛應用，這類聚合物能夠與口腔黏膜保持緊密接觸。這不僅延長了藥物在口腔黏膜上的停留時間，也實現了更可預測的吸收。這項轉變正推動著薄膜、多層貼片和可溶性基質的研發，這些製劑能夠遞送小分子藥物、具有合適滲透策略的胜肽類藥物以及需要快速起效或可控暴露的治療藥物。

人工智慧對口腔黏膜給藥的累積影響

人工智慧正成為口腔黏膜給藥系統整個價值鏈的關鍵驅動力，尤其是在製劑開發、材料選擇、生產最佳化和臨床證據生成方面。人工智慧模型透過分析溶解度、分子量、結晶質、結晶度和穩定性等理化性質，幫助篩檢輔料、聚合物、遞送增強劑以及藥物-聚合物相互作用。這減少了反覆的實驗室測試，並有助於口腔黏膜薄膜、片劑和貼片的合理製劑設計。

關於口腔黏膜給藥系統的關鍵區域見解

亞太地區正成為口腔給藥系統領域一個充滿活力的市場，這主要得益於醫療保健覆蓋範圍的擴大、龐大的患者群體、不斷提升的藥品生產能力以及對價格合理且患者易用的劑型日益成長的需求。中國、印度、日本、韓國和澳洲在價值鏈的各個環節都發揮著重要作用，從學名藥和專科製劑的研發到先進的臨床研究和監管科學。該地區慢性病負擔沉重、戒菸需求旺盛、疼痛管理需求迫切以及兒童和老年醫療保健需求不斷成長，這些因素共同推動了人們對口腔膜、片劑、噴霧劑和粘膜粘附平台等口腔給藥系統的廣泛關注。

北約、七國集團、金磚國家、歐盟、東協和海灣合作理事會的關鍵集團分析

北約成員國與北美和歐洲高度監管的藥品市場高度重疊，在這些地區，穩健的醫療供應鏈、緊急準備和可靠的基本藥物取得途徑日益重要。口腔給藥系統能夠實現快速、便攜、非侵入性的給藥方式，從而減少在緊急情況和現場對負責人給藥的依賴，進而支持這些優先事項。

關於口腔給藥系統的關鍵國家見解

中國憑藉其製劑研發、不斷擴大的國內創新、龐大的患者群體和大規模的藥品生產，為口腔給藥價值鏈做出了重要貢獻。美國是口腔給藥系統的主要市場，這得益於其先進的臨床研究體系、嚴格的法律規範、對專科藥物的廣泛應用，以及對疼痛、成癮治療、神經系統疾病、荷爾蒙療法和急診醫學等領域非侵入性治療的需求。在日本，人口老化、高標準的品質要求以及對患者友善劑型的重視，正在推動粘膜給藥技術的應用。同時，印度憑藉其強大的學名藥生產能力、先進的製劑研發能力和成本效益高的生產能力，在可規模化生產的口腔膜劑和片劑的開發中發揮著至關重要的作用。

為行業領導者提供的實用建議

業界領導者應從研發早期階段就優先考慮以患者為中心的製劑設計，最佳化口味掩蔽、口腔感受、黏附性、崩壞、劑量柔軟性和包裝便利性。口腔製劑的設計必須充分考慮實際給藥條件，包括飲水困難、吞嚥困難、需要看護者參與、兒童接受度、老年人手部靈活性以及隱藏使用等。

口腔黏膜藥物傳遞系統分析的調查方法

一套嚴謹的口腔給藥系統分析調查方法結合了二手資料研究、一手檢驗、法規審查、科學文獻評估和質性產業分析。二手資料研究應包括同行評審期刊、藥典、法規指南、臨床試驗註冊資訊、專利資料庫、公共衛生資料集和政府衛生出版刊物。這確保了研究結果是基於檢驗的科學和法規證據。

結論

由於其非侵入性給藥、潛在的生物利用度優勢、快速或可控的藥物釋放以及提高患者用藥便利性，口腔給藥系統在現代藥物創新中日益重要。其在慢性病管理、急性病護理、疼痛管理、成癮治療、荷爾蒙療法、小兒科、老年醫學和專科醫學等領域的重要性日益凸顯。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：口腔黏膜給藥系統市場：依產品類型分類

  • 電影
    • 纖維素衍生物
    • 天然聚合物
    • 合成聚合物
  • 凝膠
    • 水凝膠
    • 有機凝膠
  • 修補
    • 黏性貼片
    • 矩陣補丁
  • 噴
    • 多驅動
    • 單作用型
  • 藥片
    • 咀嚼片
    • 錠劑
    • 黏膜黏附片

第8章：口腔黏膜給藥系統市場：依藥物類別分類

  • 止痛藥
    • Buprenornhine
    • Fentanyl
  • 心血管系統
  • 中樞神經系統
  • 荷爾蒙
    • 雌二醇
    • 睪固酮

第9章：口腔黏膜給藥系統市場：依應用領域分類

  • 心血管治療
  • 荷爾蒙療法
  • 疼痛管理
  • 精神病學

第10章：頰黏膜注射系統市場：依最終使用者分類

  • 診所
  • 居家照護
  • 醫院

第11章：口腔黏膜給藥系統市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章：頰黏膜注射系統市場：依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第13章：口腔黏膜給藥系統市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第14章：頰粘膜注射系統市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Adare Pharmaceuticals Inc.
  • Applied Pharma Research SA
  • AstraZeneca plc
  • Bausch Health Companies Inc.
  • Bayer AG
  • BioDelivery Sciences International, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Endo International plc
  • Ethypharm SAS
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson
  • Medlab Clinical Ltd.
  • NAPP Pharmaceuticals Ltd.
  • Novartis AG
  • Novo Nordisk A/S
  • Perrigo Company plc
  • Pfizer Inc.
  • Roche Holding AG
  • Sandoz Group AG
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
  • Sunovion Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-3A2E844FF422

The Buccal Drug Delivery Systems Market is projected to grow by USD 6.42 billion at a CAGR of 6.74% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.06 billion
Estimated Year [2026] USD 4.33 billion
Forecast Year [2032] USD 6.42 billion
CAGR (%) 6.74%

Buccal Drug Delivery Systems Executive Summary

Buccal drug delivery systems are gaining strategic relevance as healthcare providers, pharmaceutical developers, and payers seek dosage forms that improve patient adherence, bypass first-pass hepatic metabolism, and enable rapid or controlled systemic absorption through the oral mucosa. These systems include buccal films, tablets, patches, sprays, gels, and mucoadhesive formulations designed to remain in contact with the cheek lining long enough to release active pharmaceutical ingredients effectively. Their clinical value is particularly significant for therapies where swallowing is difficult, gastrointestinal degradation is a concern, needle-free administration is preferred, or fast onset of action is important.

The sector is shaped by advances in polymer science, mucoadhesive excipients, permeation enhancers, precision manufacturing, and patient-centric formulation design. Demand is supported by the rising burden of chronic diseases, expanding geriatric populations, pediatric formulation needs, pain management requirements, hormonal therapies, smoking cessation support, emergency medicine use cases, and neurological or psychiatric treatment applications. Regulatory expectations around quality, safety, bioequivalence, extractables and leachables, mucosal tolerability, and human factor performance are also influencing product development pathways.

Themes defining the buccal drug delivery systems landscape include oral transmucosal drug delivery, mucoadhesive buccal films, controlled-release buccal tablets, non-invasive drug delivery, patient-centric dosage forms, and advanced pharmaceutical formulation technologies. As the industry evolves, success increasingly depends on balancing bioavailability, residence time, taste masking, mucosal tolerability, manufacturing reproducibility, stability, packaging integrity, and regulatory evidence generation.

Transformative Shifts in the Buccal Drug Delivery Landscape

The buccal drug delivery landscape is undergoing transformative shifts as formulation science moves from conventional oral dosage adaptation toward purpose-built transmucosal platforms. A major change is the growing use of mucoadhesive polymers that can maintain intimate contact with the buccal mucosa, improving drug residence time and enabling more predictable absorption. This shift supports the development of thin films, multilayer patches, and dissolvable matrices that can deliver small molecules, peptides with suitable permeability strategies, and therapies requiring rapid onset or controlled exposure.

Patient experience is becoming a central design criterion. Taste masking, flexible dosing, discreet administration, portability, and reduced need for water are increasingly important in clinical use and commercial adoption. These attributes are especially relevant for pediatric, geriatric, oncology-supportive care, mental health, pain, addiction treatment, and emergency treatment settings. In parallel, pharmaceutical manufacturing is shifting toward scalable film casting, hot-melt extrusion, 3D printing research, continuous processing, and improved in-process quality controls to strengthen batch consistency.

Regulatory and clinical evidence expectations are also reshaping development strategies. Developers are placing greater emphasis on mucosal safety, local irritation testing, pharmacokinetic comparability, usability studies, child-resistant and senior-friendly packaging, and packaging integrity. The landscape is further influenced by the global push toward alternatives to injections where feasible, the need for differentiated lifecycle management of established molecules, and increasing interest in delivery technologies that can support decentralized care and self-administration.

Cumulative Impact of Artificial Intelligence on Buccal Delivery

Artificial intelligence is becoming an important enabler across the buccal drug delivery systems value chain, particularly in formulation development, material selection, manufacturing optimization, and clinical evidence generation. AI-enabled models can help screen excipients, polymers, permeation enhancers, and drug-polymer interactions by analyzing physicochemical properties such as solubility, molecular weight, ionization, permeability, crystallinity, and stability. This can reduce iterative laboratory cycles and guide rational formulation design for buccal films, tablets, and patches.

In product development, machine learning supports quality-by-design approaches by identifying relationships between process parameters and critical quality attributes, including film thickness, tensile strength, drug content uniformity, disintegration time, adhesion, moisture sensitivity, and release profile. AI-driven analytics can also assist in optimizing manufacturing conditions such as drying temperature, coating uniformity, mixing parameters, residual solvent control, and packaging requirements. These capabilities are especially valuable where small deviations can affect mucosal adhesion, dose accuracy, or absorption performance.

Artificial intelligence is also contributing to clinical and post-market intelligence. Natural language processing can analyze adverse event narratives, patient feedback, literature signals, and usability data to identify tolerability or adherence patterns. Digital biomarkers and connected health records may help characterize real-world medication use where buccal therapies are prescribed. However, AI adoption must remain aligned with validated datasets, regulatory transparency, data integrity, cybersecurity, privacy safeguards, and explainable decision-making. Its cumulative impact is strongest when used to augment scientific judgment rather than replace experimental validation.

Key Regional Insights for Buccal Drug Delivery Systems

Asia-Pacific is becoming a highly active region for buccal drug delivery systems due to expanding healthcare access, large patient populations, increasing pharmaceutical manufacturing capabilities, and rising demand for affordable, patient-friendly dosage forms. China, India, Japan, South Korea, and Australia support different parts of the value chain, from generic and specialty formulation development to advanced clinical research and regulatory science. The region's chronic disease burden, smoking cessation needs, pain care demand, and pediatric and geriatric medicine requirements support broader interest in buccal films, tablets, sprays, and mucoadhesive platforms.

Europe demonstrates strong demand for high-quality, patient-centric dosage forms supported by established pharmaceutical regulation, emphasis on pharmacovigilance, and research activity in advanced drug delivery technologies. The region's aging population, chronic disease burden, and strong focus on pediatric formulation compliance support the use of buccal films and tablets where swallowing difficulty or gastrointestinal limitations reduce adherence. European requirements for quality, safety, efficacy, usability, and post-authorization monitoring continue to influence global development standards for oral transmucosal drug delivery.

North America remains a key innovation hub for oral transmucosal drug delivery, supported by mature regulatory frameworks, strong clinical trial infrastructure, high adoption of specialty pharmaceuticals, and sustained focus on non-invasive drug administration. The United States and Canada emphasize evidence-based approval pathways, product quality, pharmacokinetic performance, and patient safety, making the region important for advanced buccal formulations targeting pain, neurological disorders, addiction treatment, hormone delivery, and emergency medication use.

Latin America is seeing increasing relevance for buccal drug delivery systems as healthcare systems work to improve access, adherence, and therapeutic convenience. Brazil and Mexico play central roles due to their pharmaceutical manufacturing bases, regulatory modernization efforts, and demand for chronic disease therapies. Buccal dosage forms may offer practical advantages in communities where simple administration, storage convenience, reduced need for water, and reduced clinical supervision are important.

Africa presents a distinct opportunity where buccal formulations can support accessible, non-invasive drug administration, especially when designed for stability, affordability, and ease of use. Across African markets, uptake depends on regulatory harmonization, supply chain reliability, healthcare workforce training, and cost-sensitive product design. The Middle East is increasingly investing in healthcare modernization, specialty medicine access, and pharmaceutical localization. GCC countries are particularly active in strengthening hospital systems, regulatory capacity, and medicine availability, and buccal drug delivery systems align with regional priorities around easier administration, rapid therapeutic action, and improved patient experience.

Key Group Insights Across NATO, G7, BRICS, EU, ASEAN, and GCC

NATO members overlap substantially with high-regulation pharmaceutical environments in North America and Europe, where resilient medical supply chains, emergency preparedness, and secure access to critical medicines are increasingly relevant. Buccal systems can support these priorities when they enable rapid, portable, non-invasive treatment delivery and reduce dependence on administration by trained personnel in urgent or field-based settings.

G7 economies remain influential in research, regulatory science, clinical adoption, and advanced pharmaceutical manufacturing. Their healthcare systems emphasize product differentiation, evidence-based medicine, quality assurance, pharmacovigilance, and patient-centric innovation, making them important environments for sophisticated buccal platforms. Demand is reinforced by aging populations, chronic disease management needs, opioid stewardship, neurological care, and a preference for dosage forms that improve usability without compromising safety.

BRICS countries bring scale, manufacturing depth, and rising healthcare demand to the buccal drug delivery ecosystem. China and India contribute strong formulation and production capabilities, Brazil and South Africa support regional healthcare access expansion, and Russia maintains demand across chronic and acute therapeutic categories. Adoption across BRICS markets is shaped by affordability, domestic production priorities, regulatory alignment, and the need for therapies that improve adherence.

The European Union provides a structured regulatory environment with strong emphasis on quality, safety, efficacy, pediatric suitability, and pharmacovigilance. These priorities support buccal drug delivery development where patient adherence, swallowing difficulty, or rapid onset is clinically relevant. Harmonized regulatory processes and advanced manufacturing standards make the EU a key environment for validated oral transmucosal technologies.

ASEAN countries are increasingly relevant to buccal drug delivery systems because of expanding healthcare coverage, growing pharmaceutical manufacturing participation, and rising demand for convenient oral dosage forms across diverse income settings. Population growth, urbanization, and increasing chronic disease prevalence support interest in easy-to-administer therapies, while regional regulatory cooperation continues to improve product registration efficiency and quality expectations.

The GCC is advancing healthcare infrastructure, specialty care access, and pharmaceutical security, creating a favorable environment for innovative dosage forms such as buccal films, sprays, and mucoadhesive tablets. Demand is influenced by diabetes, pain management, cardiovascular conditions, and hospital-based emergency care needs. Local manufacturing initiatives and procurement reforms may further encourage adoption when products demonstrate quality, safety, and clinical utility.

Key Country Insights for Buccal Drug Delivery Systems

China is a major contributor to the buccal drug delivery value chain through formulation research, expanding domestic innovation, large patient populations, and large-scale pharmaceutical manufacturing. The United States is a leading environment for buccal drug delivery systems due to its advanced clinical research ecosystem, strong regulatory oversight, specialty pharmaceutical adoption, and demand for non-invasive therapies in pain, addiction treatment, neurology, hormone therapy, and emergency care. Japan's aging population, high quality standards, and focus on patient-friendly dosage forms support adoption of oral transmucosal technologies, while India combines strong generic medicine production, skilled formulation development, and cost-efficient manufacturing, making it important for scalable buccal films and tablets.

Germany's pharmaceutical engineering strength and quality manufacturing environment support advanced formulation development, while the United Kingdom maintains strong clinical research, regulatory expertise, and digital health integration. Australia's research environment and regulatory rigor provide a strong setting for clinical evaluation and niche therapeutic applications. France's emphasis on healthcare access, pharmacovigilance, and patient-centered therapy aligns with buccal delivery applications. South Korea's advanced biopharmaceutical sector, manufacturing capabilities, and innovation-focused healthcare system position it as a significant contributor to next-generation buccal delivery platforms.

Italy and Spain both present opportunities linked to aging populations, chronic disease care, and demand for dosage forms that improve medication adherence. Canada emphasizes safety, health technology assessment, and patient access, supporting interest in buccal formulations that improve adherence and usability. Russia maintains demand for accessible medicines across acute and chronic indications, with domestic manufacturing priorities influencing adoption.

Brazil is an important Latin American market where domestic pharmaceutical production, regulatory strengthening, and rising chronic disease treatment needs support attention to buccal dosage forms. Mexico benefits from pharmaceutical manufacturing capacity and expanding healthcare access, with buccal systems offering potential value in chronic disease management and convenient administration.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize patient-centric formulation design by optimizing taste masking, mouthfeel, adhesion, disintegration, dose flexibility, and packaging usability from the earliest development stages. Buccal products must be designed around real-world administration conditions, including limited water access, swallowing difficulty, caregiver involvement, pediatric acceptance, geriatric dexterity, and discreet use.

Developers should strengthen quality-by-design programs that connect material attributes, process parameters, and product performance. Critical factors include polymer selection, drug loading, content uniformity, moisture control, film thickness, mechanical strength, mucosal adhesion, dissolution behavior, residual solvents, and stability under intended storage conditions. Early investment in robust analytical methods and scalable manufacturing can reduce late-stage development risk.

Regulatory strategy should be integrated early, particularly for bioequivalence, pharmacokinetic endpoints, local tolerability, human factor evaluation, extractables and leachables, and packaging validation. Companies should also build evidence around adherence, patient preference, and clinical workflow advantages, since buccal dosage forms often compete with tablets, injections, nasal sprays, and transdermal systems.

Commercial teams should evaluate therapy areas where buccal delivery offers clear differentiation, such as rapid-onset rescue therapy, addiction treatment, pain management, hormonal therapy, antiemetics, neurological disorders, smoking cessation, and populations with dysphagia. Strategic partnerships with polymer specialists, contract manufacturers, clinical research organizations, and regulatory experts can accelerate development while improving technical reliability.

Research Methodology for Buccal Drug Delivery Analysis

A rigorous research methodology for analyzing buccal drug delivery systems combines secondary research, primary validation, regulatory review, scientific literature assessment, and qualitative industry analysis. Secondary research should include peer-reviewed journals, pharmacopoeial references, regulatory guidance, clinical trial registries, patent databases, public health datasets, and government healthcare publications. This ensures that insights are grounded in verifiable scientific and regulatory evidence.

Primary research should involve structured discussions with formulation scientists, regulatory professionals, clinical pharmacologists, pharmacists, manufacturing specialists, supply chain experts, and healthcare providers experienced in oral transmucosal therapies. These interviews help validate practical barriers such as taste masking, mucosal irritation, patient compliance, process scalability, dose uniformity, and storage stability.

Analytical review should focus on formulation technology, excipient compatibility, drug permeability, pharmacokinetic behavior, manufacturing methods, clinical utility, and regulatory requirements across regions. Triangulation is essential: scientific findings should be cross-checked against clinical evidence, regulatory documentation, pharmacopoeial standards, and expert input. The methodology should avoid unsupported assumptions and should not rely on unverified projections. Instead, it should emphasize evidence-backed trends, therapeutic applications, innovation pathways, and adoption drivers.

Conclusion

Buccal drug delivery systems are becoming an important part of modern pharmaceutical innovation because they combine non-invasive administration, potential bioavailability advantages, rapid or controlled drug release, and improved patient convenience. Their relevance is increasing across chronic disease management, acute care, pain therapy, addiction treatment, hormonal therapy, pediatrics, geriatrics, and specialty medicine.

The future direction of the sector will be shaped by advances in mucoadhesive polymers, permeation enhancement, thin-film manufacturing, quality-by-design, artificial intelligence-supported formulation development, and stronger regulatory evidence. Regional and country-level adoption will depend on healthcare infrastructure, affordability, regulatory maturity, manufacturing capability, supply chain reliability, and demonstrable clinical value.

For industry leaders, the most important priorities are clear: select drug candidates where buccal delivery creates meaningful therapeutic advantage, design products around patient needs, validate safety and performance rigorously, and build scalable manufacturing systems. Organizations that align formulation science, regulatory strategy, patient experience, and evidence-based commercialization will be best positioned to succeed in the evolving buccal drug delivery systems landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Buccal Drug Delivery Systems Market, by Product Type

  • 7.1. Introduction
  • 7.2. Films
    • 7.2.1. Cellulose Derivatives
    • 7.2.2. Natural Polymers
    • 7.2.3. Synthetic Polymers
  • 7.3. Gels
    • 7.3.1. Hydrogels
    • 7.3.2. Organogels
  • 7.4. Patches
    • 7.4.1. Adhesive Patches
    • 7.4.2. Matrix Patches
  • 7.5. Sprays
    • 7.5.1. Multi Actuation
    • 7.5.2. Single Actuation
  • 7.6. Tablets
    • 7.6.1. Chewable Tablets
    • 7.6.2. Lozenges
    • 7.6.3. Mucoadhesive Tablets

8. Buccal Drug Delivery Systems Market, by Drug Class

  • 8.1. Introduction
  • 8.2. Analgesics
    • 8.2.1. Buprenorphine
    • 8.2.2. Fentanyl
  • 8.3. Cardiovascular
  • 8.4. Central Nervous System
  • 8.5. Hormones
    • 8.5.1. Estradiol
    • 8.5.2. Testosterone

9. Buccal Drug Delivery Systems Market, by Application

  • 9.1. Introduction
  • 9.2. Cardiovascular Treatment
  • 9.3. Hormone Therapy
  • 9.4. Pain Management
  • 9.5. Psychiatry

10. Buccal Drug Delivery Systems Market, by End User

  • 10.1. Introduction
  • 10.2. Clinics
  • 10.3. Home Care
  • 10.4. Hospitals

11. Buccal Drug Delivery Systems Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Hospital Pharmacy
  • 11.3. Online Pharmacy
  • 11.4. Retail Pharmacy

12. Buccal Drug Delivery Systems Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. Europe
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Africa
  • 12.6. Middle East

13. Buccal Drug Delivery Systems Market, by Group

  • 13.1. NATO
  • 13.2. G7
  • 13.3. BRICS
  • 13.4. European Union
  • 13.5. ASEAN
  • 13.6. GCC

14. Buccal Drug Delivery Systems Market, by Country

  • 14.1. China
  • 14.2. United States
  • 14.3. Japan
  • 14.4. India
  • 14.5. Germany
  • 14.6. United Kingdom
  • 14.7. Australia
  • 14.8. France
  • 14.9. South Korea
  • 14.10. Italy
  • 14.11. Canada
  • 14.12. Russia
  • 14.13. Brazil
  • 14.14. Mexico
  • 14.15. Spain

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Adare Pharmaceuticals Inc.
  • 16.2. Applied Pharma Research SA
  • 16.3. AstraZeneca plc
  • 16.4. Bausch Health Companies Inc.
  • 16.5. Bayer AG
  • 16.6. BioDelivery Sciences International, Inc.
  • 16.7. Dr. Reddy's Laboratories Ltd.
  • 16.8. Endo International plc
  • 16.9. Ethypharm SAS
  • 16.10. F. Hoffmann-La Roche Ltd.
  • 16.11. GlaxoSmithKline plc
  • 16.12. Hikma Pharmaceuticals PLC
  • 16.13. Johnson & Johnson
  • 16.14. Medlab Clinical Ltd.
  • 16.15. NAPP Pharmaceuticals Ltd.
  • 16.16. Novartis AG
  • 16.17. Novo Nordisk A/S
  • 16.18. Perrigo Company plc
  • 16.19. Pfizer Inc.
  • 16.20. Roche Holding AG
  • 16.21. Sandoz Group AG
  • 16.22. Sanofi SA
  • 16.23. Sun Pharmaceutical Industries Limited
  • 16.24. Sunovion Pharmaceuticals Inc.
  • 16.25. Takeda Pharmaceutical Company Limited
  • 16.26. Teva Pharmaceutical Industries Ltd.
  • 16.27. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL FILMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL FILMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL FILMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELLULOSE DERIVATIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CELLULOSE DERIVATIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELLULOSE DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NATURAL POLYMERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NATURAL POLYMERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NATURAL POLYMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SYNTHETIC POLYMERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SYNTHETIC POLYMERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SYNTHETIC POLYMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HYDROGELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HYDROGELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HYDROGELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ORGANOGELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORGANOGELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ORGANOGELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PATCHES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PATCHES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ADHESIVE PATCHES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ADHESIVE PATCHES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ADHESIVE PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MATRIX PATCHES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MATRIX PATCHES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MATRIX PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SPRAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SPRAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SPRAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MULTI ACTUATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MULTI ACTUATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MULTI ACTUATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SINGLE ACTUATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SINGLE ACTUATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SINGLE ACTUATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CHEWABLE TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CHEWABLE TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CHEWABLE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LOZENGES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LOZENGES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LOZENGES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MUCOADHESIVE TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MUCOADHESIVE TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MUCOADHESIVE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANALGESICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANALGESICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BUPRENORPHINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BUPRENORPHINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BUPRENORPHINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL FENTANYL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL FENTANYL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL FENTANYL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HORMONES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HORMONES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HORMONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ESTRADIOL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ESTRADIOL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ESTRADIOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL TESTOSTERONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL TESTOSTERONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL TESTOSTERONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CARDIOVASCULAR TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CARDIOVASCULAR TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CARDIOVASCULAR TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HORMONE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HORMONE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HORMONE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PSYCHIATRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PSYCHIATRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PSYCHIATRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 193. NATO BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. NATO BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. NATO BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, 2018-2032 (USD MILLION)
  • TABLE 196. NATO BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, 2018-2032 (USD MILLION)
  • TABLE 197. NATO BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, 2018-2032 (USD MILLION)
  • TABLE 198. NATO BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, 2018-2032 (USD MILLION)
  • TABLE 199. NATO BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 200. NATO BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 201. NATO BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 202. NATO BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 203. NATO BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. NATO BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. NATO BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. G7 BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. G7 BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. G7 BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, 2018-2032 (USD MILLION)
  • TABLE 209. G7 BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, 2018-2032 (USD MILLION)
  • TABLE 210. G7 BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, 2018-2032 (USD MILLION)
  • TABLE 211. G7 BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, 2018-2032 (USD MILLION)
  • TABLE 212. G7 BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 213. G7 BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 214. G7 BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 215. G7 BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 216. G7 BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 217. G7 BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. G7 BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. GCC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 259. GCC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. GCC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, 2018-2032 (USD MILLION)
  • TABLE 261. GCC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, 2018-2032 (USD MILLION)
  • TABLE 262. GCC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, 2018-2032 (USD MILLION)
  • TABLE 263. GCC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, 2018-2032 (USD MILLION)
  • TABLE 264. GCC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 265. GCC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 266. GCC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 267. GCC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 268. GCC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. GCC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. GCC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 271. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 298. JAPAN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 299. JAPAN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. JAPAN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, 2018-2032 (USD MILLION)
  • TABLE 301. JAPAN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, 2018-2032 (USD MILLION)
  • TABLE 302. JAPAN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, 2018-2032 (USD MILLION)
  • TABLE 303. JAPAN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, 2018-2032 (USD MILLION)
  • TABLE 304. JAPAN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 305. JAPAN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 306. JAPAN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 307. JAPAN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 308. JAPAN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 309. JAPAN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 310. JAPAN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 311. INDIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 312. INDIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. INDIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, 2018-2032 (USD MILLION)
  • TABLE 314. INDIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, 2018-2032 (USD MILLION)
  • TABLE 315. INDIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, 2018-2032 (USD MILLION)
  • TABLE 316. INDIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, 2018-2032 (USD MILLION)
  • TABLE 317. INDIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 318. INDIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 319. INDIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 320. INDIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 321. INDIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 322. INDIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 323. INDIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 324. GERMANY BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 325. GERMANY BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 326. GERMANY BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, 2018-2032 (USD MILLION)
  • TABLE 327. GERMANY BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, 2018-2032 (USD MILLION)
  • TABLE 328. GERMANY BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, 2018-2032 (USD MILLION)
  • TABLE 329. GERMANY BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, 2018-2032 (USD MILLION)
  • TABLE 330. GERMANY BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 331. GERMANY BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 332. GERMANY BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 333. GERMANY BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 334. GERMANY BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 335. GERMANY BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 336. GERMANY BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 337. UNITED KINGDOM BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 338. UNITED KINGDOM BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 339. UNITED KINGDOM BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, 2018-2032 (USD MILLION)
  • TABLE 340. UNITED KINGDOM BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, 2018-2032 (USD MILLION)
  • TABLE 341. UNITED KINGDOM BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, 2018-2032 (USD MILLION)
  • TABLE 342. UNITED KINGDOM BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, 2018-2032 (USD MILLION)
  • TABLE 343. UNITED KINGDOM BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 344. UNITED KINGDOM BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 345. UNITED KINGDOM BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 346. UNITED KINGDOM BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 347. UNITED KINGDOM BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 348. UNITED KINGDOM BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 349. UNITED KINGDOM BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 350. AUSTRALIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 351. AUSTRALIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 352. AUSTRALIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, 2018-2032 (USD MILLION)
  • TABLE 353. AUSTR